Efficacy of pazopanib in FGFR1-amplified uterine carcinosarcoma: A case report

• We reported the use of pazopanib in the treatment of recurrent uterine carcinosarcoma with FGFR1 amplification. • The expert tumor board recommended pazopanib for off-label use based on genetic mutations found in cancer gene panels. • Pazopanib, a multi-tyrosine kinase inhibitor, was effective against recurrent uterine sarcoma with FGFR1 amplification. • Pazopanib maintained the patient’s quality of life for a certain period.